Psoriasis :: Promising Phase 3 trial results show biologic therapy ustekinumab significantly improved psoriasis

The first reported findings from an international, Phase 3 study showed that more than two-thirds of patients with moderate to severe plaque psoriasis receiving two doses of ustekinumab (CNTO 1275) achieved at least a 75 percent reduction in psoriasis at week 12, the primary endpoint of the study, as measured by the Psoriasis Area and Severity Index (PASI 75).

Immunity :: M.D. Anderson-led team reports possible key to autoimmune disease

A human peptide that acts as a natural antibiotic against invading microbes can also bind to the body’s own DNA and trigger an immune response in the absence of an infection, a research team led by scientists at The University of Texas M. D. Anderson Cancer Center reports in an early online publication in Nature.

Allergy :: Cell that triggers symptoms in allergy attacks can also limit damage

A blood cell known as a troublemaker for triggering the itch and inflammation in allergy attacks, the mast cell, can also calm down the flare-ups, researchers from Stanford University School of Medicine have found.

Skin Cancer :: Major Gift to Rockefeller U. to Help Combat Most Serious Skin Cancers

The Paul Milstein family has donated $5.5 million to create the Milstein Medical Research Program at Rockefeller University. The initial research efforts will be in the area of skin cancer and will be led by Dr. James G. Krueger, D. Martin Carter Professor and head of the Laboratory for Investigative Dermatology at Rockefeller.

Psoriasis :: Long-term etanercept treatment reduces psoriasis severity without increased adverse events

Extended exposure to the psoriasis medication etanercept does not appear to cause more infections or adverse events than placebo, and improvements in several measures of disease severity were observed for up to 96 weeks of therapy, according to a study in the June issue of Archives of Dermatology, one of the JAMA/Archives journals.

Inflammation :: Inflammation is at the origin and progression of diseases such as diabetes or cancer

Fifteen top international specialists in this field will gather from 25-27 June for a conference entitled, ?Inflammation and Chronic Disease?, part of the ?Barcelona BioMed? conference series organised by the Institute for Research in Biomedicine (IRB Barcelona) and the Fundaci?n BBVA.